Stocks
ICU Medical Financial Statements (ICUI) |
||||||||||
| ICU Medicalsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2021 | 25.02.2022 | 31.12.2022 | 27.02.2023 | 27.02.2024 | 12.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1 271 | 1 316 | 2 280 | 2 280 | 2 259 | 2 340 | |||
| Operating Income, bln rub | 41.8 | 52.4 | -42.9 | -8.70 | 22.8 | 0.468 | ||||
| EBITDA, bln rub | ? | 194.1 | 223.5 | 187.4 | 191.5 | 307.7 | 200.1 | |||
| Net profit, bln rub | ? | 86.9 | 103.1 | -154.5 | -74.3 | -29.7 | -111.0 | |||
| OCF, bln rub | ? | 222.8 | 267.5 | -62.1 | -62.1 | 166.2 | 255.1 | |||
| CAPEX, bln rub | ? | 100.4 | 81.2 | 90.3 | 99.3 | 93.7 | 87.3 | |||
| FCF, bln rub | ? | 122.4 | 186.4 | -152.4 | -161.5 | 72.5 | 167.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 11.5 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -10.3% | ||||
| OPEX, bln rub | 325.9 | 350.2 | 740.7 | 701.3 | 717.0 | 752.9 | ||||
| Cost of production, bln rub | 809.5 | 824.8 | 1 582 | 1 582 | 1 519 | 1 586 | ||||
| R&D, bln rub | 42.9 | 47.5 | 93.0 | 93.0 | 85.3 | 88.7 | ||||
| Interest expenses, bln rub | 1.75 | 0.858 | 66.4 | 66.4 | 102.7 | 110.8 | ||||
| Assets, bln rub | 1 764 | 1 881 | 4 516 | 4 516 | 4 378 | 4 305 | ||||
| Net Assets, bln rub | ? | 1 502 | 1 616 | 2 090 | 2 090 | 2 123 | 2 049 | |||
| Debt, bln rub | 52.1 | 45.0 | 1 653 | 1 653 | 1 705 | 1 594 | ||||
| Cash, bln rub | 410.8 | 567.2 | 213.0 | 213.0 | 254.7 | 312.5 | ||||
| Net debt, bln rub | -358.6 | -522.2 | 1 440 | 1 440 | 1 450 | 1 282 | ||||
| Ordinary share price, rub | 214.5 | 237.3 | 157.5 | 157.5 | 99.7 | 100.1 | ||||
| Number of ordinary shares, mln | 20.9 | 21.2 | 23.9 | 23.9 | 24.1 | 24.4 | ||||
| Market cap, bln rub | 4 484 | 5 033 | 3 759 | 3 759 | 2 403 | 2 446 | ||||
| EV, bln rub | ? | 4 126 | 4 511 | 5 199 | 5 199 | 3 853 | 3 728 | |||
| Book value, bln rub | 1 272 | 1 384 | -342 | -342 | -220 | -216 | ||||
| EPS, rub | ? | 4.16 | 4.86 | -6.47 | -3.11 | -1.23 | -4.54 | |||
| FCF/share, rub | 5.85 | 8.79 | -6.39 | -6.76 | 3.01 | 6.87 | ||||
| BV/share, rub | 60.8 | 65.3 | -14.3 | -14.3 | -9.12 | -8.82 | ||||
| EBITDA margin, % | ? | 15.3% | 17.0% | 8.22% | 8.40% | 13.6% | 8.55% | |||
| Net margin, % | ? | 6.83% | 7.84% | -6.78% | -3.26% | -1.31% | -4.74% | |||
| FCF yield, % | ? | 2.73% | 3.70% | -4.06% | -4.30% | 3.02% | 6.86% | |||
| ROE, % | ? | 5.78% | 6.38% | -7.39% | -3.55% | -1.40% | -5.42% | |||
| ROA, % | ? | 4.93% | 5.48% | -3.42% | -1.65% | -0.68% | -2.58% | |||
| P/E | ? | 51.6 | 48.8 | -24.3 | -50.6 | -81.0 | -22.0 | |||
| P/FCF | 36.6 | 27.0 | -24.7 | -23.3 | 33.1 | 14.6 | ||||
| P/S | ? | 3.53 | 3.82 | 1.65 | 1.65 | 1.06 | 1.05 | |||
| P/BV | ? | 3.53 | 3.64 | -11.0 | -11.0 | -10.9 | -11.3 | |||
| EV/EBITDA | ? | 21.3 | 20.2 | 27.7 | 27.1 | 12.5 | 18.6 | |||
| Debt/EBITDA | -1.85 | -2.34 | 7.69 | 7.52 | 4.71 | 6.41 | ||||
| R&D/CAPEX, % | 42.8% | 58.5% | 103.0% | 93.6% | 91.1% | 101.6% | ||||
| CAPEX/Revenue, % | 7.90% | 6.17% | 3.96% | 4.36% | 4.15% | 3.73% | ||||
| ICU Medical shareholders | ||||||||||
